Obtaining a greater vision of the patient’s trip from diagnosis to treatment is of great interest to drug developers, since they aspire to produce more effective medications. Using non-small cell lung cancer (NSCLC) as an example, Purplelab and Genentech will explore how RWD takes advantage to eliminate blind spots on the patient’s trip- Informing each phase of the life cycle of a medicine, from clinical development to market access.
The web seminar will include executives from Purplelab and Dr. Ben Freiberg, the main computer systems lead with the GCS Computer Catalysts of Genentech. Genentech is owned by Roche.
Among the conversation points that the web seminar will cover is:
- How can it be used by RWD by pharmaceutical companies for the NSCLC patient trip?
- How is the “typical” trip of the patient for NSCLC?
- MAPO OF THE MATIZED PARTIES OF A PATIENT
- The value of the lever of the social determinants of the health data
- Address socioconomic barriers that can hinder the participation of clinical trial
- Use of RWD to improve clinical trial recruitment, clinical end points and inform market access strategies
To register at the Web Seminar, eliminate blind points on the patient’s trip, scheduled for 1-2 PM ET on May 22, complete the form below:
Photo: Eugene Mymrin, Getty Images
About The Author
